Brainsway – A New Era in Depression Treatment
Brainsway™ has launched a new era, with a safe, effective* drug-free solution which can restore wellbeing for depression patients. Brainsway's Deep TMS treatment (Deep Transcranial Magnetic Stimulation) is a non-invasive treatment which can stimulate the brain region responsible for depression and bring significant improvement to patients.
A generally well-tolerated outpatient depression treatment, Brainsway Deep TMS treatment does not require hospitalization or anesthesia, and entails no memory loss, no systemic side effects* and no indefinite drug regime.
Brainsway's advantages over other treatments for depression – click here to learn more.
Brainsway technology video – click here to view.
Short Sessions, Effective for a Wide Range of Depression Cases
Brainsway's Deep TMS therapy has been proven to be an effective depression treatment for a wide range of patients cases, from mild to persistent drug-resistant depression*. It has been proven to be helpful for patients who tried 1-4 types of antidepressants but did not improve. Brainsway Deep TMS sessions provide effective results in nearly half the time of other treatments (just 20 minutes compared to 37 with traditional TMS). Moreover, Brainsway Deep TMS does not require anesthesia, and entails no memory loss and no systemic side effects*.
Brief TMS Treatment
Brainsway's Deep TMS treatment requires only brief daily sessions of 20 minutes over 4-6 weeks. In each session, the patient is comfortably seated in a chair, and a cushioned helmet is gently placed over the head. The helmet generates brief magnetic fields, at an amplitude similar to that used in MRI systems. Throughout the session, patients remain alert and awake, and immediately afterwards, patients can return home independently to resume their daily routine.
* For references relating to this issue click here
Brainsway Deep TMS has been cleared by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current depressive episode (FDA 510(k) No. K122288).